Sign in

Veronica Rendo

@vrendo.bsky.social
78 followers 81 following 26 posts

Group Leader, Uppsala University 🇸🇪 | Studying brain tumor evolution and treatment resistance

PostsRepliesMedia
Veronica Rendo @vrendo.bsky.social · 06/05/2025
Better late than never! The Rendo Lab website is officially up and running 🧠 🧬 Read about our ongoing research and the wonderful team that makes it happen! rendolab.org
rendolab.org
Rendo Lab
031
Reposted by Veronica Rendo
Marta Shahbazi @marta-shahbazi.bsky.social · 29/04/2025
Working hard with @mllthingsdna.bsky.social @katemiro.bsky.social @ms01.bsky.social and @vrendo.bsky.social @embo.org #ChromoPloidy25
091
Reposted by Veronica Rendo
bendavidlab.bsky.social @bendavidlab.bsky.social · 27/04/2025
Excited to get the #EMBOChromoploidy meeting started! 3 days of fantastic science and fun in beautiful Stresa are beginning now! meetings.embo.org/event/25-ane...
meetings.embo.org
Chromosome Segregation and Aneuploidy
Aneuploidy is a hallmark of cancer and developmental disorders such as Down syndrome. Understanding how cells accomplish faithful chromosome segregation and how chromosomal instability (CIN) impacts …
1159
Veronica Rendo @vrendo.bsky.social · 19/03/2025
📣 Online now! Our study shows how recurrent focal deletions constitute a mechanism by which cancer cells can dampen toxicity due to gene amplification. www.cell.com/cell-genomic... 🧵👇:
cell.com
Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification
Wala et al. identify recurrent focal BRD4 deletions in tumors harboring larger amplifications, suggesting that these deletions may serve to limit toxic BRD4 overexpression. A CRISPR-Cas9 cell line mod...
2146
Veronica Rendo @vrendo.bsky.social · 27/02/2025
Today we celebrated my official Group Leader appointment and paper publications with bubbles and prinsesstårta, the Swedish way! 🍰🥂🍾 Skål!
160
Veronica Rendo @vrendo.bsky.social · 19/02/2025
So excited to see this paper out! An example of how window of opportunity trials can help dissect the mechanisms of response and resistance associated with targeted therapies in glioblastoma 🧠 www.science.org/doi/10.1126/... Thanks to the patients and scientific team who made this study possible.
science.org
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
In patients with glioblastoma, navtemadlin resistance is not mediated by TP53-inactivating mutations, and combination with TMZ may improve efficacy.
051
Veronica Rendo @vrendo.bsky.social · 27/01/2025
So excited to see our paper describing the class of ARGOS genes in cancer out in @naturecomms.bsky.social! 🤩 www.nature.com/articles/s41... A giant effort led with @ms01.bsky.social and executed under the mentorship of @bendavidlab.bsky.social @rameenberoukhim.bsky.social @foijer-lab.bsky.social 🧵👇:
nature.com
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer - Nature Communications
In cancer, the impact on cellular fitness of copy-number gains affecting collaterally-amplified genes remains poorly understood compared to oncogenes. Here, the authors integrate genomic data from tum...
1116